The Cyclic Nature of Atherosclerosis: Managing a Disease That Moves in Waves

Clinicians are accustomed to thinking about atherosclerosis as a linear process — a slow, relentless accumulation of plaque that progresses toward an inevitable clinical event. This model is intuitive but incomplete. The biological reality of atherosclerosis is not a straight line but a wave — a repeating cycle of inflammatory activation, tissue injury, repair, and relative quiescence that operates simultaneously at the level of individual plaques, the arterial system as a whole, and the patient's systemic inflammatory state. Recognising this cyclicity is not merely an academic refinement. It has direct consequences for how clinicians time interventions, interpret symptom patterns, and anticipate acute events. Damage and repair as a repeating unit At the level of the individual plaque, atherosclerosis is best understood as a chronic wound that never fully heals. Each episode of cap erosion or rupture initiates a reparative inflammatory response — progenitor cells are recruited, a parietal thrombus forms a temporary scaffold, fibrous tissue is laid down, and the plaque stabilises. This repair is real and often clinically silent. But it is never complete in the sense of restoring the vessel to its pre-disease state. Each cycle of damage and repair leaves the plaque subtly altered — the fibrous cap remodelled, the lipid core potentially enlarged, the local inflammatory milieu primed for the next episode. The plaque that has survived multiple cycles of disruption and repair carries within it the architectural record of each one, and is in many respects more complex and less predictable than a plaque that has never been destabilised. This cyclicity within individual plaques is mirrored at the systemic level. Atherosclerosis does not advance uniformly across all vascular territories simultaneously. New plaques form, existing plaques destabilise and heal, inflammatory activity waxes and wanes — all in a pattern that reflects the underlying rhythm of the disease rather than a steady linear progression. A patient who is clinically stable is not necessarily biologically quiescent. They may be in a phase of relative inflammatory suppression between cycles, a distinction that matters enormously for risk stratification. The seasonal signal Among the most compelling evidence for atherosclerosis as a cyclical inflammatory process is its well-documented seasonal pattern. Acute coronary syndromes cluster in winter months across diverse climates and populations — a regularity too consistent to be explained by behavioural factors alone. Cold exposure increases sympathetic tone, raises blood pressure, and promotes prothrombotic shifts in coagulation. Respiratory infections, which peak in winter, place competing demands on the mononuclear phagocyte system and introduce systemic inflammatory signals that can destabilise vulnerable plaques. The net effect is a seasonal amplification of the same biological vulnerabilities that drive atherosclerotic events at any time of year. This seasonal signal is clinically underutilised. It represents a predictable window of elevated risk — one that should prompt proactive rather than reactive management. Reviewing medication adherence, optimising anti-inflammatory and antithrombotic therapy, and heightening surveillance in high-risk patients during autumn and early winter is a rational response to a pattern the data clearly support. Implications for patient management If atherosclerosis moves in cycles, then management strategies built on static risk models will always be partially blind to the disease's actual behaviour. A single lipid panel, a single inflammatory marker, a single imaging study — each captures a snapshot of a dynamic process at one point in its cycle. Interpreted without reference to that cycle, it may be misleading. A patient whose CRP is low at a routine visit may be in a trough between inflammatory peaks, not in a state of genuine stability. This argues for longitudinal thinking in atherosclerosis management — not simply tracking whether biomarkers are above or below threshold, but attending to their direction and velocity over time. A rising trend in inflammatory markers in a previously stable patient, even within nominally normal ranges, may signal an approaching cycle of increased disease activity. Similarly, a patient who reports a cluster of minor symptoms — transient fatigue, vague chest discomfort, minor functional changes — that resolve spontaneously may be describing a cycle of subclinical plaque destabilisation and repair rather than a benign fluctuation to be reassured away. Therapeutic timing also deserves reconsideration in this context. The cyclic nature of atherosclerosis suggests that the period immediately following an acute event — when the inflammatory cascade is active and the reparative cycle is under way — may be a window of particular therapeutic leverage. Intervening aggressively during this phase, when biological processes are already mobilised, may be more effective than equivalent intervention during a quiescent period. Conversely, procedural interventions timed poorly relative to a patient's inflammatory cycle may encounter a less favourable biological environment than the same procedure performed weeks later. A more honest disease model Atherosclerosis does not respect the administrative rhythm of annual check-ups and scheduled reviews. It has its own rhythm — cyclical, dynamic, and responsive to a wide range of internal and external perturbations. Aligning clinical management with that rhythm, rather than imposing a static framework onto a dynamic disease, is the next frontier in atherosclerosis care. It requires greater longitudinal attention to individual patients, more sophisticated use of inflammatory biomarkers as dynamic rather than static measures, and a willingness to act on patterns rather than waiting for thresholds to be crossed. The disease moves in waves. Clinical management should learn to move with them. You can learn more by reading my e-book or listening to my audiobook